SAVA241011P23500
- 0.59
- 0.000.00%
Cassava Sciences Newsroom
PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday
This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
H.C. Wainwright Upgrades Cassava Sciences(SAVA.US) to Buy Rating, Announces Target Price $116
Express News | Cassava Shares up 6.3% Premarket After Co Decides to Settle SEC Charges on Alzheimer's Drug Trial Claims
Cassava Sciences Advances Alzheimer's Trials Amid SEC Settlement
Cassava Sciences Price Target Announced at $116.00/Share by HC Wainwright & Co.
Cassava Sciences to Announce Top-line Results of ReTHINK Trial Before Year-end
Cassava Sciences up 8% at $27.44 in Pre-market Following CEO Letter
Cassava Sciences CEO Rick Barry Issues Open Letter
Cassava Sciences Analyst Ratings
Express News | Cassava Sciences- Agreed to Settle Charge of 'negligently Making Inaccurate Disclosures' Related to 2020 Phase 2B Clinical Study
Express News | Cassava Sciences Inc - Will Separate CEO and Board Chair Roles
Express News | Cassava Sciences Inc - Do Not Anticipate DOJ Will Charge Co or Seek Resolution From Co
Express News | Cassava Sciences Inc : H.c. Wainwright Raises to Buy From Neutral
Cassava Sciences Upgraded to Buy From Neutral at H.C. Wainwright
10 Health Care Stocks Whale Activity In Today's Session
Catalyst Watch: Tesla's Robotaxi Reveal, AI Events for Nvidia, AMD, and HP Enterprise
Express News | Watching Cassava Sciences; Shares See Volume As Traders Circulate Martin Shkreli X Post Mentioning The Stock
Cassava Sciences Put Volume Heavy and Directionally Bearish